MTA1 and prostate carcinoma: When combined with SAHA, a clinically approved HDAC inhibitor, Pterostilbene enhanced sensitivity to SAHA treatment by targeting MTA1 and HDAC via the same pathway in prostate cancer (Butt et al., 2017).